Ixazomib-Associated Skin Exfoliation.
作者信息
Zhang Yali, Zhao Long, Guo Yuancheng, Liu Bei
机构信息
First Clinical School of Medicine, Lanzhou University, Lanzhou, China.
Department of Hematology, First Hospital of Lanzhou University, Lanzhou, China.
出版信息
Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022045. doi: 10.4084/MJHID.2022.045. eCollection 2022.
Abstract
摘要
相似文献
1
Ixazomib-Associated Skin Exfoliation.伊沙佐米相关的皮肤剥脱
Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022045. doi: 10.4084/MJHID.2022.045. eCollection 2022.
2
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.在未经治疗的多发性骨髓瘤患者中，口服蛋白酶体抑制剂伊沙佐米与来那度胺和地塞米松联合使用的安全性和耐受性：一项开放标签的 1/2 期研究。
Lancet Oncol. 2014 Dec;15(13):1503-1512. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14.
3
Ixazomib inhibits myeloma cell proliferation by targeting UBE2K.依沙佐米通过靶向 UBE2K 抑制骨髓瘤细胞增殖。
Biochem Biophys Res Commun. 2021 Apr 16;549:1-7. doi: 10.1016/j.bbrc.2021.02.048. Epub 2021 Feb 26.
4
Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.一名多发性骨髓瘤患者中与伊沙佐米相关的急性胰腺炎
Acta Haematol. 2018;139(1):67-70. doi: 10.1159/000484655. Epub 2018 Feb 2.
5
[Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime].口服伊沙佐米-来那度胺-地塞米松方案用于复发难治性多发性骨髓瘤的长期无进展生存
Orv Hetil. 2021 Sep 5;162(36):1451-1458. doi: 10.1556/650.2021.32179.
6
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.多发性骨髓瘤患者意外过量使用伊沙佐米。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211013230. doi: 10.1177/23247096211013230.
7
T-cell pseudolymphoma secondary to ixazomib for multiple myeloma.继发于伊沙佐米治疗多发性骨髓瘤的T细胞假性淋巴瘤。
Skin Health Dis. 2021 Jun 30;1(3):e57. doi: 10.1002/ski2.57. eCollection 2021 Sep.
8
Medication use evaluation of the financial and clinical implications of ixazomib compared to bortezomib in the outpatient setting.在门诊环境下，比较 ixazomib 与硼替佐米的药物使用评估：经济和临床影响。
J Oncol Pharm Pract. 2021 Mar;27(2):279-282. doi: 10.1177/1078155220915963. Epub 2020 Apr 11.
9
Ixazomib for the treatment of multiple myeloma.伊沙佐米用于治疗多发性骨髓瘤。
Expert Opin Investig Drugs. 2015;24(9):1287-98. doi: 10.1517/13543784.2015.1065250. Epub 2015 Jul 3.
10
Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis.来那度胺相关的心血管不良事件在多发性骨髓瘤中的作用：一项系统评价和荟萃分析。
Drug Chem Toxicol. 2022 Jul;45(4):1443-1448. doi: 10.1080/01480545.2020.1835945. Epub 2020 Oct 27.
本文引用的文献
1
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.通过基因组分析鉴定的一组新诊断骨髓瘤的高危、双重打击群体。
Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.
2
Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.
J Coll Physicians Surg Pak. 2018 Jun;28(6):S89-S90. doi: 10.29271/jcpsp.2018.06.S89.
3
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤中与伊沙佐米联合来那度胺/地塞米松相关不良事件的管理
Br J Haematol. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9.
4
Practical Management of Lenalidomide-Related Rash.来那度胺相关皮疹的实际管理
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S64-9. doi: 10.1016/j.clml.2015.02.008.
5
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.在未经治疗的多发性骨髓瘤患者中，口服蛋白酶体抑制剂伊沙佐米与来那度胺和地塞米松联合使用的安全性和耐受性：一项开放标签的 1/2 期研究。
Lancet Oncol. 2014 Dec;15(13):1503-1512. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14.
6
Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.来那度胺在多发性骨髓瘤中的实际应用方法：加拿大共识
Adv Hematol. 2012;2012:621958. doi: 10.1155/2012/621958. Epub 2012 Oct 14.
7
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.来那度胺皮肤不良事件：1例原发性浆细胞白血病患者在接受来那度胺和地塞米松治疗后发生史蒂文斯-约翰逊综合征（SJS）。
Support Care Cancer. 2012 Jul;20(7):1585-7. doi: 10.1007/s00520-012-1481-0. Epub 2012 May 5.
8
Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.来那度胺治疗异基因移植后多发性骨髓瘤复发后出现的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症重叠综合征。
Ann Hematol. 2012 Feb;91(2):287-9. doi: 10.1007/s00277-011-1235-y. Epub 2011 Apr 15.
9
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.评估蛋白酶体抑制剂 MLN9708 在人类癌症的临床前模型中的作用。
Cancer Res. 2010 Mar 1;70(5):1970-80. doi: 10.1158/0008-5472.CAN-09-2766. Epub 2010 Feb 16.
Zotero 插件